Differential radiation protection of salivary glands versus tumor by tempol with accompanying tissue assessment of tempol by magnetic resonance imaging

Clinical Cancer Research

Volumn 13, Issue 16, 2007, Pages 4928-4933

  Cotrim, Ana P ^a   Hyodo, Fuminori ^b   Matsumoto, Ken Ichiro ^b   Sowers, Anastasia L ^b   Cook, John A ^b   Baum, Bruce J ^a   Krishna, Murali C ^b   Mitchell, James B ^b  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; HYDROXYLAMINE; NITROXIDE; PILOCARPINE; POLY(METHYL METHACRYLATE); TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C3H MOUSE; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; SALIVARY GLAND; SALIVARY GLAND TUMOR; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ANIMALS; CYCLIC N-OXIDES; FEMALE; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; SALIVARY GLANDS; SPIN LABELS;

EID: 34548068806     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0662     Document Type: Article

References (33)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment of the consequences of head and neckr adiotherapy. Crit Rev Oral Biol Med 2003;14:213-25.
4. Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212.
5. Nagler RM. The enigmatic mechanism of irradiation-induced damage to the major salivary glands. Oral Dis 2002;8:141-6.
6. Konings AW, Coppes RP, Vissink A. On the mechanism of salivary gland radiosensitivity. Int J Radiat Oncol Biol Phys 2005;62:1187-94.
7. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002;13:181-209.
8. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006;12:229-41.
9. Yuhas JM. Efficacy testing of WR-2721 in Great Britain everything is black and white at the gray lab. Int J Radiat Oncol Biol Phys 1983;9:595-8.
10. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003;4:378-81.
11. Vitolo JM, Cotrim AP, Sowers AL, et al. The stable nitroxide Tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin Cancer Res 2004;10:1807-12.
12. Cotrim AP, Sowers AL, Lodde BM, et al. Kinetics of Tempol for prevention of xerostomia following head and neck irradiation in a mouse model. Clin Cancer Res 2005;11:7564-8.
13. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005;44:265-76.
14. Matsumoto K, Hyodo F, Matsumoto A, et al. High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res 2006;12:2455-62.
15. Hyodo F, Matsumoto K, Matsumoto A, Mitchell JB, Krishna MC. Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res 2006;66:9921-8.
16. Metz JM, Smith D, Mick R, et al. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res 2004;10:6411 -7.
17. Cuscela D, Coffin D, Lupton G, et al. Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies. Cancer J Sci Am 1996;2:273-8.
18. Hahn SM, Sullivan FJ, DeLuca AM, et al. Evaluation of Tempol radioprotection in a murine tumor model. Free Radic Biol Med 1997;22:1211-6.
19. Gariboldi MB, Ravizza R, Petterino C, Castagnaro M, Finocchiaro G, Monti E. Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - a potential new therapeutic agent for gliomas. Eur J Cancer 2003;39:829-37.
20. Soule BP, Hyodo F, Matsumoto KI, et al. The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007;5:1-10.
21. Mitchell JB, DeGraff W, Kaufman D, et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, Tempol. Arch Biochem Biophys 1991;289:62-70.
22. Hahn SM, Tochner Z, Krishna CM, et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 1992;52:1750-3.
23. Mitchell JB, Samuni A, Krishna MC, et al. Biologically active metal-independent superoxide dismutase mimics. Biochemistry 1990;29:2802-7.
24. Xavier S, Yamada K, Samuni AM, et al. Differential protection by nitroxides and hydroxylamines to radiation-induced and metal ion-catalyzed oxidative damage. Biochim Biophys Acta 2002;1573:109-20.
25. Swartz HM, Sentjurc M, Morse PDn. Cellular metabolism of water-soluble nitroxides: effect on rate of reduction of cell/nitroxide ratio, oxygen concentrations, and permeability of nitroxides. Biochim Biophys Acta 1986;888:82-90.
26. Krishna MC, English S, Yamada K, et al. Overhauser enhanced magnetic resonance imaging for tumor oximetry: coregistration of tumor anatomy and tissue oxygen concentration. Proc Natl Acad Sci U S A 2002;99:2216-21.
27. Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Semin Oncol 2002;29:61-2.
28. Cook JA, Pass HI, Iype SN, et al. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 1991;51:4287-94.
29. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004;14:259-66.
30. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-8.
31. Yuhas JM, Storer VB. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 1969;42:331-5.
32. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino) ethylphosphorthioic acid. Cancer Res 1980;40:1519-24.
33. Andreassen CN, Grau C, Lindegaard JC. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 2003;13:62-72.